Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
XLO Xilio Therapeutics
Do not show
Hide blank lines
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
6.72% 24.55M 28.47% 21.22M 37.54% 75.04M -5.04% 19.56M
Selling and administrative expenses
57.85% 8.31M 28.68% 6.3M 123.94% 23.86M 180.19% 8.2M
-General and administrative expense
57.85% 8.31M 28.68% 6.3M 123.94% 23.86M 180.19% 8.2M
Research and development costs
-8.45% 16.25M 28.39% 14.92M 16.57% 51.19M -35.74% 11.35M
Operating profit
-6.72% -24.55M -28.47% -21.22M -37.54% -75.04M 5.04% -19.56M
Net non-operating interest income expense
Other net income (expense)
64.94% -61K 12.24% -129K -15.24% -756K 18.08% -145K
Other non- operating income (expenses)
64.94% -61K 12.24% -129K -15.24% -756K 18.08% -145K
Income before tax
-6.18% -24.61M -28.12% -21.35M -37.27% -75.8M 5.16% -19.7M
Income tax
Net income
-6.18% -24.61M -28.12% -21.35M -37.27% -75.8M 5.16% -19.7M
Net income continuous Operations
-6.18% -24.61M -28.12% -21.35M -37.27% -75.8M 5.16% -19.7M
Minority interest income
Net income attributable to the parent company
-6.18% -24.61M -28.12% -21.35M -37.27% -75.8M 5.16% -19.7M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-6.18% -24.61M -28.12% -21.35M -37.27% -75.8M 5.16% -19.7M
Basic earnings per share
-3.53% -0.9 -24.79% -0.78 -552.82% -13.52 -25.81% -0.98
Diluted earnings per share
-3.53% -0.9 -24.79% -0.78 -552.82% -13.52 -25.81% -0.98
Dividend per share
Currency Unit
Accounting Standards
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
CEO: Russo BCPS, Pharm.D, Pharm.D., Rene
Market: NASDAQ
Futu Hot List
SymbolLatest price%Chg


Back to the Top